A thermophilic streptococcus capable of increasing serotonin level and its application

By screening out the strain of Streptococcus thermophilus GDMCC No. 60810, the problem of failure to effectively utilize Streptococcus thermophilus in host metabolism regulation in the prior art was solved, and the serotonin level and Bifidobacteria intestinal abundance was achieved significantly improved serotonin levels and Bifidobacteria intestinal abundance was achieved. , suitable for dairy processing and drug development, with safe and healthy characteristics.

CN116064272BActive Publication Date: 2024-12-03JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210831191.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-14
Publication Date
2024-12-03
Estimated Expiration
2042-07-14

AI Technical Summary

Technical Problem

The prior art has failed to effectively utilize the role of Streptococcus thermophilus in host metabolism regulation, and lacks effective strains to increase serotonin levels, which affects its application in dairy processing and fermentation.

Method used

S. thermophilus GDMCC No. 60810 strain was screened from Xining area of ​​Qinghai. This strain can significantly increase the host serotonin level and increase the abundance of Bifidobacterium in the intestine, with good gastrointestinal tolerance and in vivo proliferation ability. , for the preparation of compositions for food and pharmaceuticals.

Benefits of technology

Streptococcus thermophilus GDMCC No. 60810 significantly improves serotonin levels in the serum, promotes the abundance of Bifidobacterium in the intestine, has safe and healthy properties, and is suitable for the preparation of various foods and medicines, improves flavor and relieves depression, Symptoms such as anxiety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116064272B_ABST
    Figure CN116064272B_ABST
Patent Text Reader

Abstract

The present invention discloses a thermophilic streptococcus with the ability to increase serotonin levels and its application, and belongs to the field of dairy processing and fermentation technology. The present invention screened a thermophilic streptococcus GDMCC No.60810 from yak Qula in Xining, Qinghai. This strain is a food-grade safe strain and can significantly increase the serotonin level in animal serum, with an increase of 6.7 times. In addition, the thermophilic streptococcus GDMCC No.60810 has good tolerance to the gastrointestinal tract and can increase the abundance of bifidobacteria in the intestine. Therefore, the thermophilic streptococcus GDMCC No.60810 can be used to prepare various foods and microbial preparations, and can also be used to prepare medicines for diseases such as depression, anxiety symptoms, PTSD symptoms and Parkinson's disease related to serotonin changes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a thermophilic streptococcus capable of improving serotonin level and application thereof, belonging to the technical field of dairy product processing and fermentation. Background Art

[0002] Serotonin is an important monoamine neurotransmitter in the brain, and more than 90% of serotonin is produced by the conversion of tryptophan by enterochromaffin cells in the colon. Studies in recent years have shown that the effects of serotonin on the body may be affected by intestinal microorganisms. Certain microorganisms in the intestine have the ability to produce serotonin. At the same time, the microbiome and its metabolites (such as butyrate) can regulate the body's serotonin levels by affecting the activity of tryptophan hydroxylase or the metabolic destination of tryptophan. In turn, serotonin and its reuptake inhibitors can regulate the composition and function of intestinal microorganisms. As an important signaling molecule connecting intestinal microorganisms and the brain, serotonin plays an important role in regulating the nervous system, gastrointestinal function, body lipid metabolism and the immune system. Studies have shown that serotonin is related to the regulation of emotions, energy, memory and other functions, and the lack of serotonin is closely related to the occurrence of depression.

[0003] The intestinal flora is involved in the regulation of the central nervous system and peripheral nerve function. Studies have shown that bioactive nutrients and intestinal flora can change DNA methylation and histone characteristics through various mechanisms, and microorganisms in the human intestine may play an important role in regulating various elements of the brain-brain axis. At present, some bifidobacteria and lactobacilli can regulate nerve function: Patent CN11454024A discloses a strain of Lactobacillus rhamnosus that can increase the content of the neurotransmitter 5-hydroxytryptamine in the brain, Patent CN107523526A discloses a strain of Lactobacillus reuteri that can increase the level of neurotransmitter 5-hydroxytryptamine in rat peripheral blood, Patent CN113215034A discloses a strain of Bifidobacterium breve that can increase the content of 5-hydroxytryptamine in the serum of Alzheimer's mice, and Patent CN113512514A discloses a strain of Lactococcus lactis that can increase the level of central 5-hydroxytryptamine.

[0004] Streptococcus thermophilus is one of the important fermentation strains for the development of the dairy industry. Most of the research on Streptococcus thermophilus focuses on its fermentation characteristics, such as its effects on the acid production, flavor formation and texture characteristics of fermented milk. As a commonly used food fermentation strain, it will be of great significance if the role of Streptococcus thermophilus in host metabolic regulation after ingestion can be further explored. Summary of the invention

[0005] The inventors screened a strain of thermophilic Streptococcus from the yak Qula in Xining, Qinghai. This strain can significantly improve the host's serotonin level and increase the abundance of Bifidobacterium in feces. This provides theoretical guidance for the study of thermophilic Streptococcus strain diversity and its application, and can enrich my country's fermentation bacteria library resources, which is of great significance to the development of the industry.

[0006] The first object of the present invention is to provide a strain of Streptococcus thermophilus, which was screened out from yak Qula collected in Xining, Qinghai, my country, and was deposited in Guangdong Provincial Microbiological Culture Collection Center on October 16, 2019, with a deposit number of GDMCC No.60810, and a deposit address of 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0007] In one embodiment, the thermophilic Streptococcus GDMCC No.60810 strain has the following properties:

[0008] (1) The strain can significantly upregulate serotonin levels in host serum;

[0009] (2) The strain can significantly promote the abundance of Bifidobacterium in the intestine;

[0010] (3) The strain has good gastrointestinal tolerance and in vivo proliferation ability.

[0011] The second object of the present invention is to provide a method for culturing the thermophilic streptococcus GDMCC No.60810, wherein the thermophilic streptococcus is inoculated into an M17 culture medium and cultured at 35-40°C.

[0012] The third object of the present invention is to provide a composition containing the thermophilic Streptococcus GDMCC No.60810.

[0013] In one embodiment, the composition contains one or more substances selected from the group consisting of a live strain of Streptococcus thermophilus GDMCC No. 60810, a dried strain of Streptococcus thermophilus GDMCC No. 60810, a metabolite of Streptococcus thermophilus GDMCC No. 60810, an inactivated Streptococcus thermophilus GDMCC No. 60810, a fermentation broth of Streptococcus thermophilus GDMCC No. 60810, a lysate of Streptococcus thermophilus GDMCC No. 60810, or an extract of Streptococcus thermophilus GDMCC No. 60810.

[0014] In one embodiment, the number of viable thermophilic Streptococci in the composition is not less than 5×10 9 CFU / mL or 5×10 9 CFU / g.

[0015] A fourth object of the present invention is to provide a product containing the composition.

[0016] In one embodiment, the product includes but is not limited to a microbial agent, a food or a medicine.

[0017] In one embodiment, the product is used to increase serotonin levels and / or enhance the abundance of bifidobacteria in the intestine.

[0018] Preferably, the product is used to increase serotonin levels in serum.

[0019] More preferably, the product can increase the level of serotonin in serum to alleviate or regulate depression symptoms, anxiety symptoms, PTSD symptoms and Parkinson's disease.

[0020] In one embodiment, the medicine contains the thermophilic Streptococcus GDMCC No. 60810, a drug carrier and / or a pharmaceutical excipient.

[0021] In one embodiment, the drug carrier comprises microcapsules, microspheres, nanoparticles and / or liposomes.

[0022] In one embodiment, the pharmaceutical excipient comprises an excipient and / or an additive.

[0023] In one embodiment, the excipient comprises a binder, a filler, a disintegrant and / or a lubricant.

[0024] In one embodiment, the additive comprises a solubilizer, a co-solvent, a latent solvent and / or a preservative.

[0025] In one embodiment, the dosage form of the drug is powder, granules, capsules, tablets, pills or oral liquid.

[0026] In one embodiment, the viable count of Streptococcus thermophilus GDMCC No.60810 in the product is not less than 5×10 9 CFU / mL or 5×10 9 CFU / g.

[0027] In one embodiment, the food is a health food; or the food is a dairy product, a bean product or a fruit and vegetable product produced using a starter containing the thermophilic Streptococcus GDMCC No.60810; or the food is a beverage or a snack containing the thermophilic Streptococcus GDMCC No.60810.

[0028] In one embodiment, the fermented food is produced by fermentation using the thermophilic Streptococcus GDMCC No. 60810, including solid food, liquid food, and semi-solid food.

[0029] In one embodiment, the fermented food includes dairy products, bean products or fruit and vegetable products; the dairy products include milk, yogurt, sour cream or cheese; the bean products include soy milk and sour soy milk; the raw materials of the fruit and vegetable products include yellow peaches, hawthorns, cucumbers, carrots, beets, celery or cabbage products.

[0030] In one embodiment, the method for preparing the starter is to inoculate the thermophilic Streptococcus GDMCC No. 60810 into a culture medium at an inoculum amount of 2 to 4% of the total mass of the culture medium, and culture at 37° C. for 18 hours to obtain a culture solution; centrifuge the culture solution to obtain bacterial cells; wash the bacterial cells with physiological saline three times and then resuspend them with a freeze-drying protective agent to obtain a resuspension; freeze-dry the resuspension by a vacuum freezing method to obtain a starter.

[0031] In one embodiment, a lyophilization protectant is added to the resuspension before lyophilization, and the mass ratio of the lyophilization protectant to the bacteria is 2:1.

[0032] In one embodiment, the lyoprotectant is skimmed milk powder with a concentration of 130 g / L.

[0033] Beneficial effects of the present invention:

[0034] 1. The thermophilic Streptococcus GDMCC No. 60810 of the present invention can significantly increase the level of serotonin in serum from 0.47 mg / L to 3.6 mg / L, with an increase of 6.7 times, so that it can play a regulatory role in symptoms related to serotonin changes, such as depression, anxiety symptoms, PTSD symptoms and Parkinson's disease;

[0035] 2. Streptococcus thermophilus GDMCC No.60810 can significantly promote the abundance of bifidobacteria in the intestine, good gastrointestinal tolerance and in vivo proliferation ability;

[0036] 3. Streptococcus thermophilus GDMCC No.60810 is a safe strain that can be used in food. No other chemicals are added. It is safe and healthy. It can be used to prepare various foods, medicines, and microbial preparations to improve the flavor of the products.

[0037] Biomaterial Deposit

[0038] The thermophilic streptococcus provided by the present invention is taxonomically named Streptococcus thermophilus, and was deposited in Guangdong Provincial Microbiological Culture Collection Center on October 16, 2019, with a deposit number of GDMCC No: 60810, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is a colony photo of Streptococcus thermophilus GDMCC No.60810 on M17 solid culture medium;

[0040] Figure 2 This is a Gram-stained photo of Streptococcus thermophilus GDMCC No.60810 observed under a 1000x microscope;

[0041] Figure 3 The changes of serotonin in mouse serum increased by Streptococcus thermophilus GDMCC No.60810;

[0042] Figure 4 The thermophilic Streptococcus GDMCC No.60810 promoted the presence of Bifidobacterium in mouse feces;

[0043] Figure 5 To evaluate the gastrointestinal tolerance and in vivo proliferation of Streptococcus thermophilus GDMCC No.60810.

[0044] Figure 6 The growth of Streptococcus thermophilus GDMCC No.60810 in skim milk fermentation;

[0045] Figure 7 The acid production of Streptococcus thermophilus GDMCC No.60810 in skim milk fermentation;

[0046] Figure 8 It is the content of volatile substances in skim milk fermented with thermophilic Streptococcus GDMCC No.60810. DETAILED DESCRIPTION

[0047] definition

[0048] As used herein, the following terms have the following definitions.

[0049] "Serotonin" or 5-hydroxytryptamine (abbreviated "5HT") is commonly known as a neurotransmitter in the CNS, and is involved in emotional processing (affecting mood) and cognition.

[0050] As used herein, the term "strain" refers to a microorganism of a particular species having common characteristics. Unless otherwise indicated, the terms "strain" and "cell" are used interchangeably herein.

[0051] The term "plate" used in this article refers to plate culture medium, which is the most commonly used form of solid culture medium for obtaining pure culture of microorganisms. It is a solid surface of culture medium formed in a sterile culture dish after cooling and solidification, and is often referred to as a culture plate or plate.

[0052] The term "medium" as used herein refers to a culture medium comprising the chemical elements required for the growth of the microorganisms together with at least one carbon source and one nitrogen source.

[0053] M17 liquid medium (1L): 5.0g soytone, 2.5g peptone, 2.5g casein peptone, 2.5g yeast extract powder, 5.0g beef extract powder, 5.0g lactose, 0.5g sodium ascorbate, 19.0g sodium β-glycerophosphate, 0.25g magnesium sulfate, pH value is 7.2±0.2. After adding distilled water to completely dissolve, the pH is between 6.8 and 7.2, and sterilize at 115℃ for 20min.

[0054] M17 solid medium (1 L): Prepare according to M17 liquid medium, then add 18 g agar powder. Sterilize at 115°C for 20 min.

[0055] Male C57BL / 6 mice were purchased from Beijing Weitonglihua Company.

[0056] Control strain LMD9: a commercial fermentation culture purchased from the China Industrial Microbiological Culture Collection. It has been reported in the literature that LMD9 has a certain in vivo colonization ability and a certain in vivo regulatory effect. Therefore, LMD9 was used as a control strain in the study of host regulation of Streptococcus thermophilus.

[0057] Serum metabolite detection method: Carefully draw 100 μL of serum into a 1.5 mL centrifuge tube; add 400 μL of methanol (pre-cooled at -20°C in advance) to precipitate protein, which will produce a large amount of white floccules; vortex for 30 seconds, place the sample in a -20°C refrigerator for 1 hour to increase the protein precipitation rate; centrifuge at 15000 rpm for 15 minutes at 4°C; take 400 μL of supernatant and evaporate to dryness. Add 100 μL of methanol: water (4:1, v / v) and vortex for 30 seconds to re-dissolve; centrifuge at 15000 rpm for 15 minutes at 4°C, transfer an appropriate volume of supernatant into a sample vial for testing; QC preparation: transfer an equal volume from the prepared sample to a new sample vial and mix evenly; Blank preparation: 1 mL of methanol: water (4:1, v / v) to the sample vial and mix evenly. Metabolome analysis was performed using an UltiMate 3000 HPLC system (Thermo Fisher Scientific, MA, USA) coupled to a high-resolution Q-Exactive mass spectrometer (Thermo Fisher Scientific, MA, USA) in full scan mode. Chromatographic separation of metabolites was performed using a Waters Acquity UPLCHSS reverse phase T3 column (Waters, M, USA; 2.1×100 mm×1.8 μm) at 35°C.

[0058] The present invention is described in detail below in conjunction with the embodiments described in the accompanying drawings, wherein the same numerals in all the accompanying drawings represent the same features. Although specific embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present invention and to fully convey the scope of the present invention to those skilled in the art.

[0059] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the following description of suitable methods and material examples is illustrative only and does not limit the present invention in any way.

[0060] Second, "one embodiment" or "an embodiment" as referred to herein refers to a particular feature, structure, or characteristic that may be included in at least one implementation of the present invention.

[0061] Example 1: Isolation and identification method of thermophilic Streptococcus GDMCC No.60810 strain

[0062] (1) Prepare appropriate sample dilution gradient and culture

[0063] Take out the Yak Qula from Xining, Qinghai, which was stored in a -80℃ refrigerator and thaw it on ice. After shaking and mixing, take 0.5 mL of the sample and add it to 4.5 mL of sterile saline to complete a 10-fold dilution. After shaking and mixing, take out 0.5 mL of the dilution and add it to 4.5 mL of sterile saline to complete a second 10-fold dilution. Repeat this process until the dilution reaches 10. -6 , take 100 μL from each gradient dilution, spread it evenly on the M17 solid culture medium plate, invert it, and culture it at 37℃ under anaerobic conditions for 36 to 48 hours, and observe it in time.

[0064] (2) Line separation and purification

[0065] After taking out the plates with colonies, select the gradient plates with obvious single colonies, pick colonies with different colony morphologies, and perform secondary streaking until all single colonies are purified.

[0066] (3) Gram staining and catalase test

[0067] Pick a single colony onto a glass slide, and examine under a microscope after smearing, drying, fixing, primary staining, washing, mordanting, washing, decolorization, restaining, washing, and drying. Record the Gram staining results (see Figure 2 ); and pick a single colony on a slide, add 3% hydrogen peroxide solution, observe whether bubbles are generated, and record the catalase contact results.

[0068] (4) Preservation of bacterial strains

[0069] After purification, a single colony of each strain was picked into 5 mL of liquid M17 medium and cultured at 37°C under anaerobic conditions for 20 to 24 hours. 1 mL of bacterial solution was transferred to a bacterial preservation tube and centrifuged at 6000 rpm for 3 minutes. The supernatant was discarded and 1 mL of 37% sterile glycerol solution was added, resuspended, and stored at -80°C.

[0070] (5) 16S rDNA sequence amplification

[0071] Pipette 1mL of bacterial solution and centrifuge at 6000rpm for 3min, discard the supernatant, wash twice with water, centrifuge and discard the supernatant to obtain bacterial sludge, which is used as a template for PCR amplification. The process is as follows:

[0072] 1) Amplification system 20 μL:

[0073] The template volume was 1 μL, the bidirectional primers were 1 μL each, the Taq enzyme MasterMix was 10 μL, and ddH 2 O is 7 μL.

[0074] The primers used were 27F and 1492R.

[0075] 27F: AGA GTT TGA TCC TGG CCT CA (SEQ ID No. 1),

[0076] 1492R: GGT TAC CTT GTT ACG ACT T (SEQ ID No. 2).

[0077] 2) Amplification conditions:

[0078] Pre-denaturation: 95℃3min,

[0079] First step denaturation: 94℃1min,

[0080] Second step annealing: 60℃37s,

[0081] The third step extension: 72℃2min,

[0082] Number of cycles: 37 cycles,

[0083] Step 4: Final extension: 72℃5min,

[0084] Step 5: Maintain: 12℃ for 10min.

[0085] (6) Agarose gel electrophoresis

[0086] Weigh 80mL of agarose and add it to a conical flask, add 80mL of 1×TAE, heat intermittently in a microwave for 4 minutes until the liquid is clear and transparent, cool slightly, add 4μL of nucleic acid dye, shake well, and pour into a gel plate tank. After cooling for 40 minutes to solidify, place it in an electrophoresis tank, remove bubbles, add PCR amplification products in sequence, add 2μL of PCR amplification products to each well, run the gel at 120V for 15 minutes, take out after the end, place it in a gel electrophoresis imager to take a picture and save it, record the number of the successful PCR sample, and store the successful PCR product in a -20℃ refrigerator.

[0087] (7) Sequencing and identification

[0088] The samples with successful PCR were sent to Invitrogen (Shanghai) Trading Co., Ltd. for testing. According to the sequence results fed back (sequencing results are shown in SEQ ID NO.1), BLAST search was performed in the sequence database of the National Center for Biotechnology Information (NCBI) (http: / / www.ncbi.nlm.nih.gov / blast), and the strain information with the highest matching degree was selected for result recording. After analysis and identification, the strain provided by the present invention is Streptococcus thermophilus.

[0089] Example 2: Streptococcus thermophilus GDMCC No.60810 increases serotonin levels in mouse serum

[0090] Healthy male C57BL / 6 mice weighing 18-20g were selected as experimental animal strains and divided into three groups: normal control group (Control), thermophilic Streptococcus control strain LMD9 group and thermophilic Streptococcus GDMCC No.60810 group. The strain groups were intragastrically administered with the corresponding strains every day at a concentration of 10% per mouse. 9 CFU / mouse; the normal control group was gavaged with the same volume of saline. All groups had free access to water and food. The weight and food intake of mice were tested twice a week. On the 28th day, the mice were fasted for 12 hours after gavage, anesthetized and the eyeballs were quickly removed to collect blood, and then the mice were killed by cervical dislocation. Blood samples were collected from the killed mice, and the blood samples were placed at 4°C for 1 hour, centrifuged at 3000rpm for 15 minutes, and the upper serum was carefully collected. The serum metabolites were tested, and the measured serotonin content in the serum was as follows: Figure 3 .

[0091] Depend on Figure 3It can be seen that compared with the Control group, thermophilic Streptococcus GDMCC No. 60810 can cause significant changes in serotonin in the serum of normal mice, from 0.47 mg / L in the control to 3.6 mg / L, an increase of 6.7 times. At the same time, it is significantly greater than the 0.8 mg / L of the control strain LMD9. Therefore, thermophilic Streptococcus GDMCC No. 60810 has the function of significantly regulating serotonin in serum.

[0092] Example 3: Streptococcus thermophilus GDMCC No. 60810 promotes the proliferation of Bifidobacterium in mouse feces

[0093] Healthy male C57BL / 6 mice weighing 18-20g were selected as experimental animal strains and divided into three groups: normal control group (Control), thermophilic Streptococcus control strain LMD9 group and thermophilic Streptococcus GDMCC No.60810 group. The corresponding strain was intragastrically administered every day at a concentration of 10% per mouse. 9 CFU / mouse, all groups were allowed free drinking water and food intake. The weight and food intake of mice were tested twice a week. On the 28th day, the feces of mice in each group were collected, placed on ice, and then immediately transferred to a -80°C refrigerator. DNA in the feces was extracted using a DNA rapid extraction kit according to the instructions. The V3-V4 region of the sample 16SrDNA was PCR amplified, and the amplified fragment was purified and recovered using a gel recovery kit. High-throughput sequencing was performed on the Illuminamiseq pe300 platform, and the amplicon was analyzed using the QIIME2 analysis platform.

[0094] Changes in serum serotonin are regulated to a certain extent by intestinal microorganisms. Some microorganisms in the intestine have the ability to produce serotonin. At the same time, the microbiome and its metabolites can regulate the body's serotonin levels by affecting the activity of tryptophan hydroxylase or the metabolic destination of tryptophan. Studies have shown that changes in bifidobacteria are closely related to the body's serotonin levels. Figure 4 It can be seen that compared with the Control group, after 28 days of gavage, Streptococcus thermophilus GDMCC No. 60810 can significantly increase the abundance of Bifidobacterium in feces from 2.8% to 7.0%, which is consistent with the result that Streptococcus thermophilus GDMCC No. 60810 can significantly increase the content of serotonin in serum. However, the control strain LMD9 significantly reduced the abundance of Bifidobacterium.

[0095] Example 4: Evaluation of gastrointestinal tolerance and in vivo proliferation of Streptococcus thermophilus GDMCC No. 60810

[0096] (1) Inoculate the thermophilic Streptococcus GDMCC No. 60810 stored at -80°C into M17 liquid culture medium, culture at 37°C for 24 h, and subculture 2 to 3 times until the bacterial concentration reaches 10 8 ~10 9CFU / mL; Take out 10μL of bacterial solution activated in M17 medium and add it to 0.99mL of simulated gastric fluid and simulated intestinal fluid, and vortex for 3 times at medium speed on a vortex mixer. Incubate the bacterial solution added to simulated gastric fluid at 37℃ for 0h, and perform the viable bacteria count experiment after 2h. Incubate the bacterial solution added to simulated intestinal fluid at 37℃ for 0h, and perform the viable bacteria count experiment after 1h.

[0097] The simulated gastric and intestinal fluids were prepared as follows:

[0098] ①Simulated gastric fluid:

[0099] Weigh a certain amount of pepsin (Sigma, p7000) and dissolve it in 2 / 3 of the required volume of physiological saline (0.5% w / v), adjust the pH to 3.0 with concentrated hydrochloric acid, filter with a 0.22 μm sterile filter membrane and adjust the volume to the required volume to make the final concentration reach 3 g / L. Prepare the simulated gastric fluid and use it immediately.

[0100] ②Simulated intestinal fluid:

[0101] Weigh a certain amount of trypsin (Sigma, p1500) and bile salt (oxoid, LP0055) and dissolve them in 2 / 3 of the required volume of physiological saline (0.5% w / v), adjust the pH to 8.0 with 0.1 mol / L NaOH, filter with a 0.22 μm sterile filter membrane and adjust the volume to the required volume, so that the final concentrations reach 1 g / L and 0.3%, respectively. Prepare the simulated intestinal fluid and use it immediately.

[0102] Depend on Figure 5 A shows that, compared with the control strain, the thermophilic Streptococcus GDMCC No. 60810 strain has higher in vitro acid and bile resistance, indicating that the thermophilic Streptococcus GDMCC No. 60810 has good gastrointestinal tolerance.

[0103] (2) Determination of intestinal proliferation ability of Streptococcus thermophilus

[0104] According to the animal experiment design of Example 3, feces were collected on days 0, 7, and 28 to detect the amount of thermophilic Streptococcus in the feces. DNA was extracted from feces using a DNA rapid extraction kit according to the instructions, and after amplification using thermophilic Streptococcus specific primers, the absolute biomass of thermophilic Streptococcus was detected using a qPCR instrument.

[0105] The primer sequences are:

[0106] F: 5'-TTATTTGAAAGGGGCAATTGCT-3';

[0107] R: 5'-GTGAACTTTCCACTCTCACAC-3'.

[0108] At the same time, under continuous strain intervention, the proliferation capacity of thermophilic Streptococcus in vivo increased significantly after 7 days of intragastric administration and remained stable on the 7th and 28th days ( Figure 5 B). This indicates that GDMCC No.60810 may have a good proliferation ability in the intestine.

[0109] Example 5: Growth of Streptococcus thermophilus GDMCC No.60810 in skim milk fermentation

[0110] The thermophilic Streptococcus GDMCC No.60810 stored at -80℃ was inoculated into M17 liquid culture medium and cultured at 37℃ for 24h. The culture was subcultured 2-3 times until the bacterial concentration reached 10 8 ~10 9 CFU / mL; take out the activated bacterial solution in M17 medium and inoculate it into skim milk at a volume ratio of 2% to make the bacterial count in the system reach 10 6 ~10 7 CFU / g; Place the inoculated sample in a 42°C incubator for fermentation, take samples every 6 hours, and detect the changes in the amount of bacteria during the fermentation process. The results are as follows Figure 6 shown.

[0111] Depend on Figure 6 It can be seen that after 6 hours of fermentation, the number of viable bacteria of Streptococcus thermophilus GDMCC No. 60810 increased by about 1.5 orders of magnitude, and reached the same number of viable bacteria as LMD9 after 24 hours of fermentation. Therefore, Streptococcus thermophilus GDMCC No. 60810 has good growth ability in skim milk and can be selected as a slow fermentation strain.

[0112] Example 6: Acid production of Streptococcus thermophilus GDMCC No.60810 in skim milk fermentation

[0113] The thermophilic Streptococcus GDMCC No.60810 stored at -80℃ was inoculated into M17 liquid culture medium and cultured at 37℃ for 24h. The culture was subcultured 2-3 times until the bacterial concentration reached 10 8 ~10 9 CFU / mL; take out the activated bacterial solution in M17 medium and inoculate it into skim milk at a volume ratio of 2% to make the bacterial count in the system reach 10 6 ~10 7 CFU / g; the inoculated samples were placed in a 42°C incubator for fermentation, and samples were taken every 6 hours to detect the changes in pH during the fermentation process. The results were as follows Figure 7 As shown. Figure 7 It can be seen that after 12h of fermentation, the pH of Streptococcus thermophilus GDMCC No. 60810 reached 4.94, and at 24h, the pH reached 4.53. LMD9 produced more acid quickly during 12h and 24h of fermentation, indicating that Streptococcus thermophilus GDMCC No. 60810 can be used as a slow fermentation strain for fermented milk, and it may slow down the post-acidification process.

[0114] Example 7: Content of volatile substances in Streptococcus thermophilus GDMCC No.60810 after skim milk fermentation

[0115] Fermentation was carried out according to the fermentation conditions of Examples 5 and 6, and samples were taken after 12 h to determine the content of volatile substances in the fermented milk.

[0116] The determination method of volatile substances is as follows: Gas chromatography conditions and temperature program: select Rtx-WAX capillary (30m×0.25mm, 0.25mm), injection port temperature 225℃, split ratio 10, carrier gas (helium) flow rate 1mL / min. The temperature program sets the initial temperature to 30℃, maintain for 3min, increase the temperature to 225℃ at 15℃ / min, and maintain for 5min; mass spectrometry conditions: ionization mode EI, emission energy 70eV, emission current 200μA, detector voltage 1.4kV, ion source temperature 240℃, interface temperature 230℃, quadrupole temperature 150℃, mass scanning range m / z 30~500; the spectrum obtained by GC-MS is searched in the NIST 2001 standard spectral library and compared with standards for qualitative identification of substances, and quantitative analysis is performed using the peak area normalization method. Results are shown in Figure 8 .

[0117] Depend on Figure 8 It can be seen that the acetaldehyde and acetoin produced by thermophilic Streptococcus GDMCC No. 60810 after fermentation for 12 hours are higher than those of strain LMD9, especially the content of acetoin is more than 2 times that produced by LMD9, which can reach 24μg / Kg. It can provide a creamy taste for fermented milk. Therefore, thermophilic Streptococcus GDMCC No. 60810 has excellent aroma production characteristics.

[0118] Example 8: Preparation of a microbial agent containing Streptococcus thermophilus GDMCC No.60810

[0119] Streptococcus thermophilus GDMCC No.60810 was streaked on M17 solid culture medium and cultured at 37°C for 48 hours to obtain a single colony; a single colony was picked and inoculated into MRS liquid culture medium, cultured at 37°C for 18 hours for activation, and activated for two generations to obtain an activation solution; the activation solution was inoculated into the culture medium at an inoculum amount of 2-4% of the total mass of the culture medium, and cultured at 37°C for 18 hours to obtain a bacterial solution; the bacterial solution was centrifuged at 8000g for 10 minutes to obtain a bacterial sludge; the bacterial sludge was washed with physiological saline for 3 times and then resuspended with a protective agent to a concentration of 1×10 10 CFU / mL, and a bacterial suspension was obtained, namely, a liquid bacterial agent; the bacterial suspension was pre-cultured at a temperature of 37°C for 60 minutes and then freeze-dried to obtain thermophilic Streptococcus GDMCC No.60810 bacterial powder.

[0120] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. Streptococcus thermophilus ( Streptococcus thermophilus ) in the preparation of a drug for relieving depression symptoms, anxiety symptoms, PTSD symptoms and Parkinson's disease; characterized in that, The thermophilic Streptococcus was deposited in the Guangdong Provincial Microbiological Culture Collection Center on October 16, 2019, with a deposit number of GDMCC No. 60810; the medicine contains a live strain of the thermophilic Streptococcus.

2. The use according to claim 1, characterized in that: The viable count of the thermophilic streptococcus in the drug is not less than 5×10 9 CFU / mL or 5×10 9 CFU / g.

3. The use according to claim 1, characterized in that: The medicine contains the live strain of Streptococcus thermophilus as claimed in claim 1, as well as a medicine carrier and / or a pharmaceutical excipient.